Status:
COMPLETED
Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium
Lead Sponsor:
Sara Rafael Fernandez
Conditions:
Infertility
Infertility, Female
Eligibility:
FEMALE
18-40 years
Phase:
PHASE2
Brief Summary
This study evaluate the percentage of women with thin endometrium who achieve an endometrial thickness equal to or greater than 7 mm after administration of PRGF (plasma rich in growth factors)
Eligibility Criteria
Inclusion
- Women who signed informed consent.
- Women who understand the Spanish language.
- Women under 42 years
Exclusion
- Thrombopenia.
- Congenital or acquired uterine malformations that reduce embryo implantation or term gestation.
- Ovarian tumors.
- Benign uterine tumors require surgical treatment
- Local acute inflammatory diseases
- Patients with malignant tumors requiring chemotherapy.
- Patients with acute or chronic infectious or inflammatory diseases requiring active treatment with drugs that may interfere with implantation and gestation.
- Chronic treatment with NSAIDs (Nonsteroidal anti-inflammatory drugs)
Key Trial Info
Start Date :
May 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 26 2022
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT03387501
Start Date
May 27 2019
End Date
July 26 2022
Last Update
September 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clinico San Carlos
Madrid, Spain, 28040